Cocrystal Pharma, Inc. (COCP) has a negative trailing P/E of -1.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -52.84%.
Criteria proven by this page:
Overall SharesGrow Score: 62/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.7 | -0.11 | 2.69 | 0.00 | - |
| 2017 | -236.1 | 2.38 | 1.37 | 0.00 | - |
| 2018 | -2.1 | 0.00 | 1.51 | 0.00 | - |
| 2019 | -0.4 | 0.02 | 0.71 | 2.79 | - |
| 2020 | -8.1 | 0.09 | 1.49 | 38.87 | - |
| 2021 | -4.2 | 0.53 | 0.77 | 0.00 | - |
| 2022 | -0.4 | 0.00 | 0.40 | 0.00 | - |
| 2023 | -0.9 | 0.01 | 0.63 | 0.00 | - |
| 2024 | -1.2 | 0.00 | 2.16 | 0.00 | - |
| 2025 | -1.3 | 0.02 | 1.75 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-38.14 | $0.00 | $-74.87M | - |
| 2017 | $-0.30 | $0.00 | $-613K | - |
| 2018 | $-21.01 | $0.00 | $-49.05M | - |
| 2019 | $-1.51 | $6.56M | $-48.19M | -734.1% |
| 2020 | $-0.17 | $2.01M | $-9.66M | -479.4% |
| 2021 | $-0.16 | $0.00 | $-14.19M | - |
| 2022 | $-4.77 | $0.00 | $-38.84M | - |
| 2023 | $0.00 | $0.00 | $-17.98M | - |
| 2024 | $-1.72 | $0.00 | $-17.5M | - |
| 2025 | $-0.78 | $0.00 | $-8.83M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.79 | $-0.97 – $-0.61 | $0.00 | $0.00 – $0.00 | 2 |
| 2027 | $-0.97 | $-0.97 – $-0.97 | $0.00 | $0.00 – $0.00 | 1 |
| 2028 | $-0.70 | $-0.70 – $-0.70 | $0.00 | $0.00 – $0.00 | 1 |
